Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

20.70 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 20.70
Bid (Size) 20.03 (4)
Ask (Size) 21.50 (2)
Prev. Close 20.70
Today's Range 20.70 - 20.70
52wk Range 16.19 - 25.77
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2
Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX® (cabozantinib) in patients with previously treated radioactive iodine-refractory... 
From Business Wire News Releases
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX®) in combination with atezolizumab in patients with... 
From Business Wire News Releases

Performance

YTD
+0.83%
+0.83%
1 Month
+7.48%
+7.48%
3 Month
+14.87%
+14.87%
6 Month
-6.25%
-6.25%
1 Year
-12.77%
-12.77%

More News

Read More
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Business Wire News Releases
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckM
From Business Wire News Releases
Exelixis Statement on the Passing of Two Senior Executives
From Business Wire News Releases
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
Tags Thyroid Cancer Movers Biotech
From Benzinga
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
From Business Wire News Releases
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2%
Tags Earnings Small Cap Benzinga
From Benzinga
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Car
From Business Wire News Releases
Got $1,000? 5 Perfect Stocks to Buy for the Fourth Quarter
Tags Market News EXEL AVGO
From Motley Fool
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
Tags EXEL ESMO21 renal cell carcinoma
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.